TABLE I.
Population eligible for rituximab treatmenta
| Parameter | Study year | ||
|---|---|---|---|
| 1 | 2 | 3 | |
| Incident patientsb in Canada | 4242 | 4284 | 4327 |
| Patients seeking treatmentc | 3733 | 3770 | 3808 |
| Eligible cases treated with rituximab | 3359 | 3393 | 3427 |
a
Includes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
b
Calculated as the Canadian-based non-Hodgkin lymphoma (NHL) incidence rate multiplied by the total Canadian population estimates for 2018–2020, considering that DLBCL and FL respectively account for 33% and 22% of all patients with NHL.
c
Further stratifies incident patients with DLBCL and FL by the proportions assumed to undertake treatment (90% for DLBCL and 85% for FL).